Abstract
The objective of this study is to explore the therapeutic effect of Tadalafil on male ED after transurethral resection of prostate (TURP). Using the 5-item version of the International Index of Erectile Function (IIEF-5), ED was assessed in 104 male patients who experienced ED after TURP. These patients were assigned randomly into the therapy group and matched group on the basis of the degree of ED. The patients of the therapy group received Tadalafil, and the patients of matched group received placebo of starch. According to their actual conditions, all patients were informed of the action mechanism and administration of Tadalafil in detail, and advised to use the drug 1 h before sexual activity as recommended. The dose was increased from 10 to 20 mg by week 2 and 4, depending on the effects and adverse reactions. After 8 weeks, ED was re-assessed by IIEF-5. In therapy group, ED was cured in 28 cases, improved in 17 cases, and nonresponsive in 7 cases, with an overall effective rate of 86.5%. In matched group, ED was cured in 6 cases, improved in 7 cases, and non-responsive in 39 cases, with an overall effective rate of 25%. The statistical difference was significant (P<0.05). No significant adverse reaction was observed in any patient. In conclusion, Tadalafil is safe and effective, and can be used as the first-line medication for the clinical treatment of post-TURP ED.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Taher A . Erectile dysfunction after transurethral resection of the prostate: incidence and risk factors. World J Urol 2004; 22: 457–460.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM . Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319–326.
Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U . Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000; 12: 305–311.
Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB et al. Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int (Randomized Controlled Trial Research Support, Non-US Gov't) 2011; 107: 1943–1947.
Magheli A, Burnett AL . Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol (Review) 2009; 6: 415–427.
Tenhunen R, Marver HS, Schmid R . Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 1969; 244: 6388–6394.
Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168 (4 Part 1): 1332–1336.
Goldstein I, Kim E, Steers WD, Pryor JL, Wilde DW, Natanegara F et al. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007; 4: 166–175.
Tscholl R, Largo M, Poppinghaus E, Recker F, Subotic B . Incidence of erectile impotence secondary to transurethral resection of benign prostatic hyperplasia, assessed by preoperative and postoperative Snap Gauge tests. J Urol 1995; 153: 1491–1493.
Bieri S, Iselin CE, Rohner S . Capsular perforation localization and adenoma size as prognostic indicators of erectile dysfunctional after transurethral prostatectomy. Scand J Urol Nephrol 1997; 31: 545–548.
Soderdahl DW, Knight RW, Hansberry KL . Erectile dysfunction following transurethral resection of the prostate. J Urol 1996; 156: 1354–1356.
Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int (Research Support, NIH, Extramural Research Support, Non-US Gov't Research Support, US Gov't, Non-PHS) 2008; 101: 203–210.
Noviasky JA, Masood A, Lo V . Tadalafil (Cialis) for erectile dysfunction. Am Fam Physician 2004; 70: 359–360.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Yu, H., Wu, H. & Rao, D. Analysis of the therapeutic effect of Tadalafil on male ED after transurethral resection of prostate. Int J Impot Res 24, 147–149 (2012). https://doi.org/10.1038/ijir.2012.6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijir.2012.6